BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Caussy C, Aubin A, Loomba R. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. Curr Diab Rep 2021;21:15. [PMID: 33742318 DOI: 10.1007/s11892-021-01383-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Bellanti F, Lo Buglio A, Dobrakowski M, Kasperczyk A, Kasperczyk S, Aich P, Singh SP, Serviddio G, Vendemiale G. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease. World J Gastroenterol 2022; 28(26): 3243-3257 [DOI: 10.3748/wjg.v28.i26.3243] [Reference Citation Analysis]
2 Lange NF, Graf V, Caussy C, Dufour JF. PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients. Int J Mol Sci 2022;23:4305. [PMID: 35457120 DOI: 10.3390/ijms23084305] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Khouya T, Ramchoun M, Elbouny H, Hmidani A, Bouhlali EDT, Alem C. Loquat (Eriobotrya japonica (Thunb) Lindl.): Evaluation of nutritional value, polyphenol composition, antidiabetic effect, and toxicity of leaf aqueous extract. J Ethnopharmacol 2022;296:115473. [PMID: 35718052 DOI: 10.1016/j.jep.2022.115473] [Reference Citation Analysis]
4 Ryter SW. Heme Oxygenase-1: An Anti-Inflammatory Effector in Cardiovascular, Lung, and Related Metabolic Disorders. Antioxidants 2022;11:555. [DOI: 10.3390/antiox11030555] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
5 Yardeni D, Toledano R, Novack V, Shalev A, Wolak A, Rotman Y, Etzion O. The Association of Alanine Aminotransferase Levels With Myocardial Perfusion Imaging and Cardiovascular Morbidity. J Cardiovasc Pharmacol Ther 2022;27:107424842210745. [DOI: 10.1177/10742484221074585] [Reference Citation Analysis]
6 Bao S, Wang X, Ma Q, Wei C, Nan J, Ao W. Mongolian medicine in treating type 2 diabetes mellitus combined with nonalcoholic fatty liver disease via FXR/LXR-mediated P2X7R/NLRP3/NF-κB pathway activation. Chinese Herbal Medicines 2022. [DOI: 10.1016/j.chmed.2022.06.003] [Reference Citation Analysis]
7 Dabravolski SA, Bezsonov EE, Baig MS, Popkova TV, Nedosugova LV, Starodubova AV, Orekhov AN. Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk. Int J Mol Sci 2021;22:4459. [PMID: 33923295 DOI: 10.3390/ijms22094459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Chung G, Han K, Lee K, Cho E, Bae J, Yang S, Yu S, Choi S, Yim J, Heo N. Combined Effects of Chronic Kidney Disease and Nonalcoholic Fatty Liver Disease on the Risk of Cardiovascular Disease in Patients with Diabetes. Biomedicines 2022;10:1245. [DOI: 10.3390/biomedicines10061245] [Reference Citation Analysis]
9 Gutiérrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases. Int J Mol Sci 2021;22:11629. [PMID: 34769060 DOI: 10.3390/ijms222111629] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]